Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2020
The case for using novel value elements when assessing COVID-19 vaccines and therapeutics
23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...
Posted by Michael Wonder on 22 Jun 2020
Proposed legislation to stabilise ACA threatens health care innovation
22 June 2020 - This week, the Democratic led House of Representatives may introduce legislation that seeks to stabilise the ...
Posted by Michael Wonder on 21 May 2020
Drug innovation is back in fashion
21 May 2020 - Big pharma is no longer the villain. ...
Posted by Michael Wonder on 20 Apr 2020
Big pharma has the chance to come to the world’s rescue
20 April 2020 - The pandemic may finally do for the pharmaceutical industry what relentless TV advertising cannot: show off its ...
Posted by Michael Wonder on 12 Feb 2020
Australia's biotech innovations heading offshore, prompting calls for greater funding to bring them to market
11 February 2020 - The demand on the health sector has never been more evident, as the world scrambles to ...
Posted by Michael Wonder on 22 Jan 2020
Supporting innovative medicines funding in Scotland
21 January 2020 - Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure ...
Posted by Michael Wonder on 20 Jan 2020
After 20 years of using economic evaluation, should NICE be considered a methods innovator?
13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision ...
Posted by Michael Wonder on 19 Jan 2020
Is innovation causing accessibility, timing issues for private drug plans?
17 January 2020 - Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are ...
Posted by Michael Wonder on 19 Jan 2020
Closing the cycle of innovation in health care in Europe
17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...
Posted by Michael Wonder on 10 Dec 2019
Pharmacare with no new medicines
10 December 2019 - Meeting with pricing officials shows that government's true goal is to slash prices so low that no ...
Posted by Michael Wonder on 10 Dec 2019
Do large pharma companies provide drug development innovation? Our analysis says no.
10 December 2019 - Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. ...
Posted by Michael Wonder on 06 Dec 2019
Proposed changes to research and development tax incentive will discourage investment and undermine innovation
6 December 2019 - Medicines Australia is disappointed that proposed changes to the Research and Development Tax Incentive were tabled ...
Posted by Michael Wonder on 04 Dec 2019
White House claims Speaker Nancy Pelosi’s drug pricing bill would result in 100 fewer drugs over a decade
3 December 2019 - The report from the administration suggests far greater consequences for both the drug industry and American consumers ...
Posted by Michael Wonder on 26 Nov 2019
Using GRADE methodology to assess innovation of new medicinal products in Italy
25 November 2019 - In April 2017 the Italian Medicine Agency developed new criteria to grant any new medicinal product with ...
Posted by Michael Wonder on 17 Oct 2019
Pelosi’s drug pricing plan puts medical innovation at risk
17 October 2019 - The future of medical innovation in America is at a crossroads. ...